Coagulopathy (main): Difference between revisions
Elcatracho (talk | contribs) |
Elcatracho (talk | contribs) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 19: | Line 19: | ||
===Increased Clotting=== | ===Increased Clotting=== | ||
{{Increased clotting DDX}} | {{Increased clotting DDX}} | ||
==Management== | ==Management== | ||
| Line 36: | Line 33: | ||
*[[Transfusions]] | *[[Transfusions]] | ||
*[[Idarucizumab]] | *[[Idarucizumab]] | ||
*[[Procedures in patients with coagulopathies]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Heme/Onc]] | [[Category:Heme/Onc]] | ||
Latest revision as of 18:15, 17 February 2021
Background
- Primary hemostasis: damage to endothelial basement membrane and formation of platelet plug
- Secondary hemostasis: coagulation cascade
Clinical Features
- Spontaneous bleeding
- Bleeding out of proportion
- Swollen joints
- Epistaxis
- Bleeding gums
- Menometrorrhagia
- Easy bruising/petechiae
- Hematuria
Differential Diagnosis
Coagulopathy
Platelet Related
- Too few
- Nonfunctional
Factor Related
- Acquired (Drug Related)
- Warfarin (Coumadin)
- Unfractionated heparin
- Low molecular weight heparin (i.e. enoxaparin (Lovenox), dalteparin)
- Factor Xa Inhibitors (e.g. rivaroxaban, apixaban, fondaparinux, edoxaban)
- Direct thrombin inhibitors (e.g. dabigatran, argatroban, bivalirudin)
- Illness induced
- Genetic
Increased Clotting
Management
- Bleeding Treatments
- Procedures in patients with coagulopathies
- Anticoagulant reversal (known medications)
- Anti-platelet agent reversal